NASDAQ · Biotechnology

CYCN (CYCN) Stock

$3.57 +0.28% NASDAQ: CYCN Healthcare

Valuation

MetricValue
Price$3.57
Market Cap$16.71M
P/E Ratio-2.99
P/B Ratio2.04
P/S Ratio7.07
EPS (TTM)$0.00
52-Week High$8.48
52-Week Low$1.03
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-67.77%
ROA-45.81%
ROCE-55.56%
Gross Margin100.00%
Operating Margin-3.37%
Net Margin-2.65%
Debt/Equity0.00
Current Ratio5.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$0$0$2.0M$2.0M
Operating Profit$-55.0M$-19.0M$-13.0M$-4.0M$-5.0M
Net Profit$-52.0M$-44.0M$-5.0M$-3.0M$-4.0M
EPS$-26.40$-20.15$-8.99$-1.21$-1.09
Op Margin-1662.5%-6242.4%—-181.4%-239.8%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$59.0M$18.0M$13.0M$10.0M$10.0M
Total Liabilities$11.0M$8.0M$2.0M$1.0M$1.0M
Cash$54.0M$13.0M$8.0M$3.0M$3.0M
Borrowings$0$0$0$0$0

Latest News

Cyclerion Therapeutics (CYCN) Merges With Korsana Biosciences to Advance Alzheimer’s Pipeline Insider Monkey · Apr 20, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-37.0M$-41.0M$-21.0M$-4.0M$-3.0M
Investing Cash Flow$1.0M$0$10.0M$0$0
Financing Cash Flow$0$0$0$0$2.0M
Net Cash Flow$-4.0M$-41.0M$-6.0M$-4.0M$0
Free Cash Flow$-37.0M$-41.0M$-21.0M$-4.0M$-3.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-25.46%
Quick Ratio1.80
Interest Coverage—
Return 1Y16.67%
Return 3Y-9.51%
Return 5Y-94.43%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADXNAddex Therapeutics Ltd $5.89 -0.17% -0.72 $4.24M 0.00%
AIM $0.24 -5.84% -0.09 $801193 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
NBYNovaBay Pharmaceuticals, Inc. $1.47 -24.62% 0.09 $39.14M 2.72%
PLRZ $11.06 -3.74% -6.55 $12.39M 0.00%

About CYCN

CYCN is led by CEO Regina Graul, employs 1 people, headquartered in US, publicly traded since 2019.

CYCN stock trades at $3.57 with a market capitalization of $16.71M. The stock is valued at a price-to-earnings (P/E) ratio of -2.99, price-to-book of 2.04, price-to-sales of 7.07. Over the past 52 weeks the stock has ranged between $1.03 and $8.48, and currently trades 57.9% below its 52-week high.

On profitability, CYCN generates a return on equity (ROE) of -67.77%, return on capital employed of -55.56%, an operating margin of -3.37%, a net profit margin of -2.65%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides